Mesenchymal Stem Cell Transplantation in MS (CMM-EM)

This study has been terminated.

(Ended the recruitment in June 2012 for low enrollement accrual)

Sponsor:

Collaborator:

Instituto de Salud Carlos III

Information provided by (Responsible Party):

Albert Saiz, Hospital Clinic of Barcelona

ClinicalTrials.gov Identifier:

NCT01228266

First received: October 25, 2010

Last updated: February 12, 2014

Last verified: February 2014

History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study has been terminated.
Study Completion Date:	December 2013
Primary Completion Date:	June 2013 (Final data collection date for primary outcome measure)

No publications provided by Hospital Clinic of Barcelona

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Llufriu S, Sepúlveda M, Blanco Y, Marín P, Moreno B, Berenguer J, Gabilondo I, Martínez-Heras E, Sola-Valls N, Arnaiz JA, Andreu EJ, Fernández B, Bullich S, Sánchez-Dalmau B, Graus F, Villoslada P, Saiz A. Randomized placebo-controlled phase II trial of autologous mesenchymal stem cells in multiple sclerosis. PLoS One. 2014 Dec 1;9(12):e113936. doi: 10.1371/journal.pone.0113936. eCollection 2014.

To Top